Invitae
About Invitae
Invitae, now an operating subsidiary of Labcorp, is a medical genetics company that has historically focused on making comprehensive genetic information accessible to healthcare providers and patients. Utilizing Next-Generation Sequencing (NGS) technology, Invitae developed and commercialized a broad portfolio of genetic tests designed to inform clinical decision-making across various medical specialties. These offerings include diagnostic panels for hereditary cancers (such as breast, colorectal, ovarian, and prostate cancers), cardiovascular conditions (aortopathies, arrhythmias, cardiomyopathies), neuromuscular disorders, rare and pediatric diseases, and pharmacogenomics.
The company has integrated artificial intelligence and machine learning into its operations, notably through acquisitions like Jungla and Diploid (with its Moon platform), to enhance variant interpretation and facilitate the development of more comprehensive genetic testing solutions, including whole-genome offerings. Invitae also engaged in partnerships with biopharma companies to offer no-cost genetic testing programs for individuals suspected of having specific rare disorders, aiming to accelerate diagnoses and improve patient outcomes. This strategic approach aimed to aggregate a wide array of genetic tests into a single, high-quality, and cost-effective service.
In early 2024, Invitae filed for Chapter 11 bankruptcy protection and subsequently entered into an agreement for its acquisition by Labcorp. As of May 7, 2024, Labcorp completed the acquisition of Invitae’s genetic testing services, digital health solutions, and health data services. This transition positions Invitae’s capabilities within Labcorp’s broader genetic specialty testing business, continuing its mission to provide actionable genetic insights to support patients, clinicians, and pharmaceutical partners.
Focus Areas
Business Intelligence
| Key Investors | Orbimed, The Broe Group, Decheng Capital, Baker Brothers Investments, BlackRock, Casdin Capital, Redmile Group, Genesys Capital, Thomas McNerney & Partners, Genomic Health, SB Management (SoftBank Group subsidiary) [cite: 2, 15 (from previous turn), 23 (from previous turn), 38 (from previous turn)] |
| Partnerships | BridgeBio Pharma (Jan 2024) [cite: 14 (from previous turn)], Lumea (Sep 2023) [cite: 18 (from previous turn)], Prognos Health (March 2024) [cite: 30 (from previous turn)], Alnylam Pharmaceuticals, Horizon Therapeutics, Spark Therapeutics, X4 Pharmaceuticals (for rare diseases) [cite: 19 (from previous turn), 44 (from previous turn)] |
| Acquisitions | Good Start Genetics (2017) [cite: 1, 4 (from previous turn), 5 (from previous turn)], CombiMatrix (2017) [cite: 1, 4 (from previous turn), 5 (from previous turn)], ArcherDX (2020) [cite: 1, 5 (from previous turn), 7 (from previous turn), 19 (from previous turn), 38 (from previous turn)], Ciitizen (2021) [cite: 1, 5 (from previous turn), 14 (from previous turn)], Genosity (2021) [cite: 5 (from previous turn), 38 (from previous turn)], Diploid (2020) [cite: 5 (from previous turn), 19 (from previous turn), 21 (from previous turn)], YouScript (2020) [cite: 5 (from previous turn), 7 (from previous turn), 19 (from previous turn)], Genelex (2020) [cite: 5 (from previous turn), 7 (from previous turn), 19 (from previous turn)], Clear Genetics (2019) [cite: 5 (from previous turn)], Jungla (2019) [cite: 5 (from previous turn), 19 (from previous turn)], Singular Bio (2019) [cite: 5 (from previous turn)], CancerGene Connect (2017) [cite: 5 (from previous turn)], AltaVoice (2017) [cite: 5 (from previous turn)], IntelliGene Health Informatics (2021) [cite: 38 (from previous turn)]; acquired by Labcorp (2024) [cite: 1, 2, 13 (from previous turn), 24 (from previous turn), 26 (from previous turn), 37 (from previous turn)] |
| Technology | Invitae Generation™ with Clinical Variant Modeling (machine learning/AI for variant classification), Sherloc (variant classification framework), AI-assisted exome reanalysis, NGS-based sequencing services, digital health platform for genomic and clinical data integration [cite: 9 (from previous turn), 20 (from previous turn), 22 (from previous turn), 28 (from previous turn), 39 (from previous turn)] |
| FDA Clearances | 1 (Invitae Common Hereditary Cancers Panel, de novo authorization in Sep/Oct 2023) [cite: 3 (from previous turn), 6 (from previous turn), 8 (from previous turn), 11 (from previous turn), 12 (from previous turn), 22 (from previous turn)] cleared products (estimated) |
What Physicians Need to Know
For physicians, Invitae offers streamlined workflows through extensive EHR integrations, particularly with Epic's Aura, which simplifies test ordering and provides discrete results directly within existing clinical workflows, reducing administrative burden and enhancing clinical decision support. Physicians can rely on Invitae for comprehensive, medical-grade, and actionable genetic insights that can inform diagnosis, prognosis, treatment plans, and preventive strategies across various conditions. The broad test catalog caters to diverse patient needs, from adult and pediatric diagnostics to proactive health screening. Furthermore, Invitae provides dedicated support, including access to genetic experts, peer-to-peer consultations, and clinical practice resources. The company's commitment to affordability, flexible billing, and readily available genetic counseling services helps remove barriers to testing, making it easier for physicians to integrate genetic information into routine patient care. Features like VUS resolution and family testing also provide more definitive answers, aiding in patient management.
Invitae offers seamless integrations with Electronic Health Record (EHR) solutions, most notably through a partnership with Epic to integrate genetic test results directly into Epic's Aura specialty diagnostics suite. This integration allows for test result information to be available within providers' usual workflows, enhancing precision medicine and simplifying access to genetic insights. Invitae has completed over 400 customer EHR integrations, demonstrating a strong capability to connect with various healthcare systems.
What the Web Says
Invitae is a medical genetics company that offers a variety of sequencing-based genetic tests for diagnostic, proactive, and reproductive health purposes. The company aims to integrate genetic information into mainstream medicine and provides tools for medical professionals to record family history and recommend appropriate genetic testing. While Invitae has been recognized for its advanced testing technology and high standards for accuracy and privacy, it has faced significant operational challenges, including filing for bankruptcy in early 2024 and being acquired by Labcorp. This transition has led to overwhelmingly negative recent customer reviews, primarily concerning processing errors, delays, billing issues, and poor customer support. Employer reviews indicate a mixed sentiment, with many appreciating the mission-driven culture and good pay, but also highlighting concerns about mismanagement, job security, and leadership disconnect.
Overall: MixedStrengths
- Extensive collection of single-gene and panel tests for various conditions.
- Access to genetic counselors for informed customer experience.
- Health insurance may cover costs for some diagnostic tests.
- HIPAA-compliant with CLIA and CAP-certified labs, demonstrating dedication to privacy and security.
- Mission-driven company with passionate employees.
- Competitive pay and good benefits, including unlimited PTO for some roles.
Limitations
- More expensive than some other genetic tests on the market.
- Billing process can be confusing, especially with insurance reimbursements, leading to unexpected charges.
- Recent overwhelmingly negative customer reviews due to processing errors, delays, and poor customer support.
- No access to raw data, limiting cross-verification with other DNA analysis services.
- Proactive health screening tests are generally not covered by health insurance.
- Concerns about mismanagement, job security, and leadership disconnect among employees.
Based on reviews from: Nebula Genomics, Indeed.com, Nucleus, Medium, Xcode Life, Reddit, What to Expect Community, Invitae, Capterra
Last updated: 2026-07-24
Videos
News, demos, and interviews about Invitae.
Videos load interactively. If none appear, search YouTube for Invitae →
Press & Coverage
Frequently Asked Questions
Comparisons
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]